Angiosyn, Inc. is a biopharmaceutical company developing novel proprietary biologics for controlling angiogenesis.
Angiosyn, Inc. is a biopharmaceutical company developing novel proprietary biologics for controlling angiogenesis.The company's initial therapeutic indication is for ophthalmic diseases, such as macular degeneration and diabetic retinopathy, which due to angiogenesis can lead to decreased vision and blindness